approval
saveTECVAYLI (TECLISTAMAB-CQYV) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalOct 2, 2025 · 368d ago
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalAug 19, 2025 · 412d ago
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalDec 2, 2024 · 672d ago
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalNov 22, 2024 · 682d ago
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalJul 2, 2024 · 825d ago
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalMay 28, 2024 · 860d ago
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalFeb 20, 2024 · 958d ago
- approvalTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalNov 16, 2023 · 1054d ago
same company · ±60 days · 6
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalMar 5, 2026
- approvaltalquetamab: TALVEY (TALQUETAMAB-TGVS) — FDA approvalMar 5, 2026
- approvalicotrokinra hydrochloride: ICOTYDE (ICOTROKINRA HYDROCHLORIDE) — FDA approvalMar 17, 2026
- approval(amivantamab + hyaluronidase (human recombinant)): RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) — FDA approvalFeb 13, 2026
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalFeb 12, 2026
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 27, 2026
comments(0)
5-min edit window · permanent after that